Translate Bio, headquartered in Lexington, Massachusetts, USA, was a clinical-stage biotechnology company focused on developing mRNA therapeutics for the treatment of various diseases. The company's core technology centered on its proprietary mRNA platform, which aimed to deliver therapeutic mRNA molecules to cells, enabling the production of therapeutic proteins within the body. This approach had the potential to address a broad range of unmet medical needs. Note that Translate Bio was acquired by Sanofi in 2021 and no longer operates independently.

Key Focus Areas (Historical):

Translate Bio's primary therapeutic focus was on:

• Cystic Fibrosis: The company had several programs exploring mRNA-based treatments for cystic fibrosis, leveraging the mRNA platform's potential to deliver functional copies of the CFTR gene to affected cells.

• Other Rare Genetic Diseases: Beyond cystic fibrosis, Translate Bio was investigating the application of its mRNA technology to a range of other rare genetic diseases with a significant unmet need. Specific target areas may have varied throughout their operational lifespan.

Technology Platform:

The cornerstone of Translate Bio's innovation was its proprietary mRNA platform, which included:

• mRNA design and optimization: This involved creating mRNA molecules with enhanced stability, translation efficiency, and reduced immunogenicity.

• Delivery systems: The company was developing effective delivery mechanisms to ensure efficient and targeted delivery of the therapeutic mRNA to the desired cells or tissues.

Company History (Prior to Acquisition):

Translate Bio was founded with the explicit goal of translating mRNA therapeutics from research into clinical applications. The company advanced through preclinical research, and initiated various clinical trials to evaluate the safety and efficacy of its mRNA-based therapies in human subjects. The company's progress and specific trial data were publicly reported through press releases and SEC filings prior to its acquisition.

Acquisition by Sanofi:

In 2021, Translate Bio was acquired by Sanofi, a major global pharmaceutical company. This acquisition demonstrated the significant potential of Translate Bio's mRNA technology platform and its pipeline of mRNA therapeutics. Sanofi integrated Translate Bio's assets and expertise into its own research and development efforts. As a result, Translate Bio no longer exists as an independent entity.